1. Introduction {#sec1-vaccines-07-00130}
===============

Human papillomavirus (HPV) is the most common viral of the reproductive system. Most sexually-active men and women will be infected with HPV at some point in their lives, while some of them will be repeatedly infected \[[@B1-vaccines-07-00130]\]. Although the majority of virus types are harmless, over 40 of them may cause cancer. Papilloma viruses can be transmitted through vaginal, oral, or anal sex. While they privilege the genital mucosae, these viruses can also reach the throat and cause pre-cancerous or cancerous lesions \[[@B2-vaccines-07-00130]\].

Two-thirds of HPV infections are asymptomatic. The persistence of high-risk HPV types, however, can cause various types of precancerous and cancerous lesions, including cervical cancer. In addition, HPV infections are responsible for other forms of cancer that can also affect men. Low-risk HPV can cause ano-genital warts (condyloma), which are common in both men and women. Over the course of life, 1 in 10 people on average will be affected \[[@B3-vaccines-07-00130]\].

In Switzerland, more than 5000 women are diagnosed with cervical pre-cancer each year and require further tests and/or surgery. They are most often young women, although cancer can sometimes only appear 20 or 30 years after the primary HPV Infection. Despite the implementation of screening, about 250 women will present cervical cancer in Switzerland every year \[[@B4-vaccines-07-00130]\].

Among over 200 HPV types, 14 of them can infect the genital organs in both women and men. Similarly to women, while infections may disappear over the years in some men, they may also persist in others. One recent study has shown that approximately three to four million cases of genital warts occur each year in men, with a peak rate of 500 per 100,000 in the 25--29 year-old men \[[@B5-vaccines-07-00130]\]. Another study conducted in the United States of America (USA) has estimated that about 2120 men in the U.S. will be diagnosed with cancer of the penis in 2017, while about 2950 men will be diagnosed with anal cancer \[[@B6-vaccines-07-00130]\].

In Switzerland, HPV infections were the main cause of anal cancer, which is diagnosed every year in 200 new cases, 90% of which are caused by HPV type 16 and 18 \[[@B7-vaccines-07-00130]\]. HPV can also take part in the development of other cancers in the genitals (penis) and throat. These cancers were, however, much rarer than those of the cervix and anus.

The introduction of the HPV vaccination represents the most important primary prevention measure against HPV-related precancer and cancer \[[@B8-vaccines-07-00130]\]. The currently available vaccines in Switzerland are Gardasil^®^ and Cervarix^®^, both of which protect against HPV genotypes 16 and 18. Gardasil^®^, which has been available on the international market since 2007, also covers against genotypes 6 and 11, which are mostly responsible for the development of genital condylomas \[[@B9-vaccines-07-00130]\]. This 9-valent vaccine, which protects against five additional types of oncogenic HPV (HPV 31, 33, 45, 52, 58), was launched on the Swiss market in 2016. The cantonal programs, however, have integrated it in their vaccination campaigns in 2019. If vaccination is successfully started before the 15th birthday, two injections at six-month intervals are recommended, starting from the 15th birthday, three injections over a period of at least six months are necessary for optimal protection. Swiss health authorities recommend vaccination against HPV to all teenagers aged 11 to 14 years. Since HPV-related diseases occur more frequently in women than in men, vaccination is recommended for girls as one of the mandatory vaccines, while for boys it is currently considered a supplementary vaccination. Since January 2016, Gardasil^®^ 9-valent was available and free of charge for boys in the majority of the Swiss cantons. The national coverage rates in Switzerland are assessed using the cantonal rates as part of the Swiss National Vaccination Coverage Survey (SNVCS). Concerning the HPV coverage rate, the most recent data are from the period 2014--2016. A study on the 2017--2019 period is currently underway, but the results are not yet available. For the period 2014--2016, the results were as follows: For two doses, after increasing from 24% in 2008--2010 to 54% in 2011--2013, the coverage rate no longer increased significantly during the period 2014--2016 and now stands at 56%. An analysis of the dose gap shows that during the last investigation period, only 48% of girls had received a valid two- or three-dose schema

One of the main challenges for the Swiss public health HPV vaccination program is to develop accurate forms of communication and information about the HPV infection. Research has identified that health professionals play an important role in vaccines uptake. Moreover, there is a lack of initiatives to improve education among undergraduate healthcare students about HPV infection, consequences, and prevention \[[@B10-vaccines-07-00130]\]. For a large majority of these young adults (women or men), the internet is the main and only source of information.

In order to make a conscious, informed decision about the vaccine's uptake, the target population, which includes both women and men, should understand the importance of prevention through HPV vaccination, and the issues associated with the persistence of the infection.

Accurate knowledge about HPV infection and HPV vaccination are two critical points to make appropriate evidence-based health care choices. Consciousness about the knowledge of undergraduate health students on HPV infection and vaccination is important for the students themselves, but also for the society, as spreading the correct information about the vaccines is a fundamental point in ensuring community support \[[@B11-vaccines-07-00130]\].

Education of the community was, therefore, an essential step in the primary prevention of the HPV infection. This study aimed to evaluate (1) the basic knowledge and beliefs regarding HPV infections and HPV vaccines among undergraduate healthcare women and men students (nursing and midwifery) and (2) their attitudes towards the HPV vaccination.

2. Methods {#sec2-vaccines-07-00130}
==========

2.1. Population {#sec2dot1-vaccines-07-00130}
---------------

Recruitment of the study participants took place from January to March 2019 at three Schools of Health Sciences located in Switzerland. Men and women aged 18 years or older, currently attending these three Schools of Health Sciences to obtain a nursing or midwifery degree in their first year, second year, or third year, were invited to participate in the study.

2.2. Study Design {#sec2dot2-vaccines-07-00130}
-----------------

Announcements about the study were given by previously informed professors who were teaching classes at the School of Health Sciences. An email was also sent by the study investigators to the students prior to their recruitment.

The survey instrument was an online self-administrated anonymous questionnaire developed using SurveyMonkey software (Palo Alto, CA, USA). This software automatically saves responses into a secure database, thus protecting the participants' confidentiality. On the first page of the web questionnaire, the participant could view a consent form, informing him/her of the study objectives and procedures. The participants had the right to refuse or terminate their participation in the study at any moment, in which case the time of study drop-out was indicated in the questionnaire. If the participants accepted to participate in the study, they were asked to tick a box in order to accept the informed consent form. If the participants did not agree to participate, the webpage automatically closed down. Three email reminders were sent at one, two weeks and three weeks after the first invitation, unless an individual requested to be removed from the mailing list throughout the process. The web-based survey was automatically closed 10 weeks after having sent the first invitation.

2.3. Study Tool {#sec2dot3-vaccines-07-00130}
---------------

The questionnaire included three parts. The first part contained items about the socio-demographic characteristics of the participants. The second part contained items about basic knowledge of the HPV infection (17 items), and basic knowledge about HPV vaccination (seven items), where he/she could answer either "yes" or "no". The third part contained items about the participants' attitude toward the HPV vaccination (six items). The content's validity was evaluated by three experts (nurse, midwife, and epidemiologist), and a feasibility study was previously performed on 15 nurses and five midwives (not publish). The questionnaire was developed in French, based on previous surveys evaluating HPV knowledge, attitudes and perceptions \[[@B12-vaccines-07-00130],[@B13-vaccines-07-00130],[@B14-vaccines-07-00130],[@B15-vaccines-07-00130],[@B16-vaccines-07-00130],[@B17-vaccines-07-00130]\].

2.4. Sample Size {#sec2dot4-vaccines-07-00130}
----------------

The total number of nursing and midwifery students enrolled at the three selected Schools of Health Sciences is around 1′200 students: A minimum sample size of *n* = 600 was calculated based on a confidence interval of 95%, a significance level of 0.05, a power of 80%, and response rate of 50%.

2.5. Statistical Analyses {#sec2dot5-vaccines-07-00130}
-------------------------

Data collected by the Survey Monkey was exported to a Microsoft Excel database. Statistical analyses were run using STATA 13. Normality of the distribution was tested by the Kolmogorov--Smirnov test. Descriptive statistics and frequencies were analyzed for all variables. The *t*-test and Chi-square test were used for the descriptive statistics and for the comparison between variables. Logistic regression models were used to assess the associations between explicative variables and the status of the HPV vaccine's uptake. The status of HPV immunization on women and men was used as the primary outcome. For this purpose, an individual was considered as vaccinated when he/she had received at least one dose of the vaccines. At the multivariate analysis, only those covariates considered to be of interest based on the univariate analysis' results were included. All the hypotheses were two-sided, and results were considered significant at 0.05.

2.6. Ethical Approval {#sec2dot6-vaccines-07-00130}
---------------------

The study protocol was approved by the ethical cantonal board in Geneva (Commission Cantonale d'Ethique et de la Recherche---CCER) with the identification number Req-2019-00118. All participants signed an informed consent form prior to taking part in the study. The trial was registered under cliniclatrials.gov with the identifiers: NCT03888599.

3. Results {#sec3-vaccines-07-00130}
==========

3.1. Participants Socio-Demographic Characteristics {#sec3dot1-vaccines-07-00130}
---------------------------------------------------

A total of 650 men and women undergraduate students accepted to participate in the study and answered the entire questionnaire online and were thus included in the study.

The participants' baseline characteristics are presented in [Table 1](#vaccines-07-00130-t001){ref-type="table"}. The mean of age was 23.1 years (range 18--35), 66% of the participants were nursing women students or midwives in their first year, second year or third year of Bachelor's degree, the other 34% were nursing men students in either their first year, second year or third of Bachelor's degree, while no midwifery man student took part in the study. The majority of the participants were Swiss (77%), 14% of them came from Europe (mainly France 10%) and 9% came from non-European countries (mainly either South America or Africa). The vast majority of the participants were not married (85%). A total of 65% of the participants were non-smokers. Overall, 9.2% of the women and men reported never having had sexual intercourse. The reported age of first intercourse of 17.5 years was the same for both women and men. A total of 14% of women students declared that they did not use a contraceptive method, 9.5% of the entire group had never used a condom, and 82% of them were sexually active.

3.2. Students Basic Knowledge about HPV {#sec3dot2-vaccines-07-00130}
---------------------------------------

[Table 2](#vaccines-07-00130-t002){ref-type="table"} shows the basic knowledge and beliefs about HPV infection and vaccination. Most of the students (women and men) knew that cervical cancer was strongly linked to the HPV infection (over 90% of positive responses), a vast majority of them was aware that HPV could to be sexually transmitted (86% of women and only 67% of men obtained positive response). The majority of women (84%) knew that HPV was responsible for genital warts, while only 61% of men answered this question. Overall, 75% of men and 42% of women believed that HPV infection could be treated with antibiotics. Nearly 50% of men students believed that men could not be infected with HPV.

3.3. HPV Vaccination's Knowledge
--------------------------------

The participants' attitudes toward HPV vaccination are reported in [Table 3](#vaccines-07-00130-t003){ref-type="table"}. We observed that nearly 95% of women and 77% of men were aware of the existence of vaccines to protect women from HPV. Over 70.7% and 70.4% of women and men students, respectively, were aware of the existence of vaccines for both women and men. A total of 60.4% of women and 55.6% of men students believed that the HPV vaccine provided protection against most sexually transmitted infections.

3.4. Attitude toward the HPV Vaccines {#sec3dot4-vaccines-07-00130}
-------------------------------------

The participants' attitudes toward HPV vaccines are reported in [Table 3](#vaccines-07-00130-t003){ref-type="table"}. A total of 72.6% and 31.4% of women and men students, respectively, had received at least one dose of the vaccines. Overall, 29.5% of women and 42.2% of men students believed that the vaccination should be administered before the first sexual intercourse. Only 28.3% and 16.6% of the women and men students, respectively, knew that the vaccines were available for both women and men. A total of 89.5% of women and 90.1% of men students responded that they would recommend the HPV vaccination to their peers.

3.5. Predictors of HPV Vaccination {#sec3dot5-vaccines-07-00130}
----------------------------------

The results of the logistic regression predicting HPV vaccination are presented in [Table 4](#vaccines-07-00130-t004){ref-type="table"}.

Women participants were five times more likely to be vaccinated than their men counterparts (aOR: 5.79, 4.06--8.25 CI 95%). Participants with a European nationality also had higher vaccination rates than those with a Swiss nationality (aOR: 1.65, 1.42--1.92 CI 95%). Not being married, never having had sexual intercourse and not being sexually active at the moment were all predictive factors for having lower vaccination rates (aOR: 0.68, 0.22--0.72 CI 95%, aOR: 0.50, 0.30--0.83 CI 95% and aOR: 0.31, 0.10--0.95 CI 95%). A non-smoking status was also a predictor of a greater likelihood of being vaccinated for HPV (aor: 1.51, 1.05 - 2.81 CI 95%).

4. Discussion {#sec4-vaccines-07-00130}
=============

This was the first study to assess knowledge about HPV infection and vaccination in a population of undergraduate men and women healthcare students in Switzerland. Previously published studies have sought to assess the prevalence of different HPV strains (only in nurses and midwife women) and the reasons and socio-demographic characteristics of the unvaccinated women \[[@B18-vaccines-07-00130],[@B19-vaccines-07-00130]\]. This study also represents the first effort in evaluating the HPV vaccination coverage rate in a population of young men.

Our findings highlight a general lack of knowledge of the HPV infection's natural history and its prevention among future Swiss nurses (men and women) and midwives (women only). The knowledge gaps of future health professionals have also been documented by studies conducted in other countries, such as Pakistan, Turkey, Lebanon, Germany, and USA \[[@B11-vaccines-07-00130],[@B13-vaccines-07-00130],[@B15-vaccines-07-00130],[@B16-vaccines-07-00130],[@B20-vaccines-07-00130]\].

Such knowledge gaps may be explained by the fact that among the three Schools of Health Sciences that participated in this study, none includes in their nursing curriculum a specific course about sexuality and HPV infection, with the exception of an optional course only available during their third year of bachelor. There is also no specific course about vaccinations in the nursing curriculum in these three schools. The topic of HPV is studied in the curriculum of midwives in a little more detail (about 2 h on their entire curriculum), two schools out of the three included in this study have a specific course (only 1 h) on vaccinations in their midwifery training curriculum.

This lack of education on HPV and other vaccines among future health professionals on the subject of vaccination (HPV, measles, and others) seems to be more frequent and is becoming a major problem due to the increasing hostility towards vaccination, particularly in the current context in Europe and the United States \[[@B21-vaccines-07-00130],[@B22-vaccines-07-00130],[@B23-vaccines-07-00130]\], where there is a growing mistrust towards vaccinations parallel to the increased incidence of vaccine-preventable diseases \[[@B24-vaccines-07-00130],[@B25-vaccines-07-00130]\].

Our study indicates that young women have a higher level of knowledge about HPV than young men. This difference can be explained by the habit of girls to go for an annual check-up with the gynecologist or physician starting at puberty. Such consultations are aimed at providing girls with information about family planning, menstruation-related issues such as dysmenorrhea, and sexually transmitted diseases \[[@B26-vaccines-07-00130],[@B27-vaccines-07-00130],[@B28-vaccines-07-00130]\]. When asked about the source of their information about sexuality in general, young girls in Switzerland tend to turn to other girls, then, secondly, to magazines for young people and finally, to the Internet, while boys cite the Internet first and other young men as second \[[@B29-vaccines-07-00130]\]. While a study conducted in the United States found that the use of video messages was a potential tool to increase knowledge about HPV \[[@B30-vaccines-07-00130]\], other trials have also shown that social networks (e.g., Facebook, Instagram, Twitter etc.) can be used as complementary tools to deliver conventional prevention messages \[[@B31-vaccines-07-00130],[@B32-vaccines-07-00130],[@B33-vaccines-07-00130]\].

Strength and Limitations of the Study {#sec4dot1-vaccines-07-00130}
-------------------------------------

One of the strengths of our study is that it is the first in Switzerland to evaluate knowledge about HPV infection and HPV vaccination on such a large sample size. It is also the first to ask men about this problem in Switzerland and to have a first approach to HPV vaccination coverage for young men.

This study has some limitations that need to be addressed. The population sample was constituted of exclusively undergraduate students, which limits the generalization of our findings to the general population. As data were also collected through a questionnaire with self-reported answers, the reliability of which could not be directly verified by the study investigators, the results could also have been altered by such means of data collection.

HPV vaccination coverage rate was calculated using self-reporting of the number of doses received by participants to be sure of the number of doses people received, a copy of their vaccination carnet should have been requested, which was not possible in the context of this study. In the absence of a blood test, we cannot be sure of their HPV immunological status. It can, therefore, be assumed that the HPV vaccination coverage rate was calculated even if it was only a secondary objective of this study underestimates or on the contrary overestimates the right vaccination coverage rate. A final limitation of our study was the fact that the sample collected was not selected randomly, but according to the participation in the study by the students. This problem limits the generalization of our results.

5. Conclusions {#sec5-vaccines-07-00130}
==============

The results of this study revealed a poor understanding among healthcare undergraduate men and women students about the HPV infection, its mode of transmission and its prevention. Nurses and midwives play a crucial role in shaping public views of HPV transmissions, prevention and vaccination. They represent a privileged channel to spread information about HPV to the target audience \[[@B34-vaccines-07-00130]\]. Future education campaigns and courses for healthcare students need to clarify multiple points about the modes of transmission of the infection, the means of prevention, including vaccination and other lesions induced by HPV in both men and women, in the view of increasing the vaccination coverage rate, and subsequently, reduce the rate of HPV-related cancers. In the future, those involved in prevention will have to make more use of the new communication channels in order to disseminate their message. Clear and targeted messages can positively influence adherence to primary and secondary preventive strategies, such as reduced risk-taking in sexual behavior or participation in HPV vaccination and cervical cancer screening.

The findings highlight the need for more HPV education among undergraduate healthcare student. It must be done to increase HPV knowledge and vaccination rates in this population.

E.J., M.V.; E.J., M.V., M.-C.F., C.K., N.O. collected data; E.J., M.V. analyzed the data; E.J., M.V., M.-C.F., C.K., N.O., E.K.M., P.V., B.K. and P.P. wrote the paper.

This study was funded by the Department of Obstetrics and Gynecology, included in Geneva University Hospitals.
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vaccines-07-00130-t001_Table 1

###### 

Socio-demographic characteristics of the study population.

                                                                 *N*      \%
  -------------------------------------------------------------- -------- -------
  **Age (mean/SD)**                                              23.1     8.16
  Range (min-max)                                                18--35   
  **Gender**                                                              
  Women                                                          427      65.7%
  Men                                                            223      34.3%
  **Birthplace**                                                          
  Switzerland                                                    502      77.2%
  Europe                                                         90       13.8%
  Other                                                          58       8.9%
  **Relationship status**                                                 
  Married                                                        554      85.2%
  Not married                                                    96       14.8%
  **Smoker**                                                              
  Yes                                                            423      65.1%
  No                                                             227      34.9%
  **Ever had sexual Intercourse**                                         
  Yes                                                            559      86.0%
  No                                                             60       9.2%
  Missing                                                        31       4.8%
  **Age of first sex encounter (mean/SD)**                       17.5     1.83
  **Number of sexual partners in lifetime (mean/SD)**            5.3      0.043
  Women                                                          3.6      7.8
  Men                                                            8.7      5.9
  **Contraceptive method (question only for women *N* = 427)**            
  vaginal ring                                                   128      30.0%
  hormonal IUD                                                   16       3.7%
  Injectable                                                     2        0.5%
  withdrawal                                                     50       11.7%
  condom                                                         171      40.0%
  no method                                                      60       14.1%
  **Condom use during sexual intercourse**                                
  Never                                                          62       9.5%
  Occasional                                                     231      35.5%
  Always                                                         357      54.9%
  **Currently sexually active**                                           
  Yes                                                            533      82.0%
  No                                                             117      18.0%

vaccines-07-00130-t002_Table 2

###### 

Knowledge and beliefs regarding HPV infections and HPV vaccines.

                                                                                          Women *N* = 427   Men *N* = 223                                     
  ------------------------------------------------------------------------------- ------- ----------------- --------------- ----- ------- ----- ------- ----- -------
  The type of cancer highly associated with HPV infection is uterine cancer       True    400               93.7%           27    6.3%    205   91.9%   18    8.1%
  HPV can be sexually transmitted                                                 True    368               86.2%           59    13.8%   150   67.3%   73    32.7%
  Having many sexual partners increases the risk of getting HPV                   True    334               78.2%           93    21.8%   135   60.5%   88    39.5%
  HPV can be passed on during sexual intercourse                                  True    298               69.8%           129   30.2%   125   56.1%   98    43.9%
  A person could have HPV for many years without knowing it                       True    267               62.5%           160   37.5%   135   60.5%   88    39.5%
  HPV always has visible signs or symptoms                                        False   231               54.1%           196   45.9%   150   67.3%   73    32.7%
  HPV is very rare infection                                                      False   285               66.7%           142   33.3%   138   61.9%   85    38.1%
  There are many types of HPV                                                     True    306               71.7%           121   28.3%   147   65.9%   76    34.1%
  Using condoms reduces the risk of getting HPV                                   True    370               86.7%           57    13.3%   187   83.9%   36    16.1%
  HPV can be passed on by genital skin to skin contact                            True    214               50.1%           213   49.9%   147   65.9%   76    34.1%
  HPV can cause genital warts                                                     True    360               84.3%           67    15.7%   136   61.0%   87    39.0%
  HPV can cause herpes                                                            False   258               60.4%           169   39.6%   141   63.2%   82    36.8%
  HPV can be cured with antibiotics                                               False   245               57.4%           182   42.6%   54    24.2%   169   75.8%
  Most sexually active people will get HPV at some point in their lives           True    201               47.1%           226   52.9%   157   70.4%   66    29.6%
  Having sex at an early age increases the risk of getting HPV                    True    220               51.5%           207   48.5%   109   48.9%   114   51.1%
  HPV usually doesn't need any treatment                                          True    235               55.0%           192   45.0%   104   46.6%   119   53.4%
  Men cannot get HPV                                                              False   350               82.0%           77    18.0%   120   53.8%   103   46.2%
  **HPV Vaccine Knowledge Questions**                                                                                                                         
  There is a vaccine to protect women from HPV                                    True    405               94.8%           22    5.2%    173   77.6%   50    22.4%
  There is a vaccine to protect men from HPV                                      True    302               70.7%           125   29.3%   157   70.4%   66    29.6%
  The HPV vaccines offer protection against all sexually transmitted infections   False   258               60.4%           169   39.6%   124   55.6%   99    44.4%
  Someone who has had HPV vaccine cannot develop cervical cancer                  False   390               91.3%           37    8.7%    168   75.3%   55    24.7%
  The HPV vaccines are most effective if given to people who have never had sex   True    367               85.9%           60    14.1%   162   72.6%   61    27.4%
  The HPV vaccines offer protection against most cervical cancers                 True    361               84.5%           66    15.5%   158   70.9%   65    29.1%
  The HPV vaccine offers protection against genital warts                         True    347               81.3%           80    18.7%   147   65.9%   76    34.1%

vaccines-07-00130-t003_Table 3

###### 

Attitudes toward HPV vaccines.

                                                                       Women *N* = 427   Men *N* = 223   *p*           
  -------------------------------------------------------------------- ----------------- --------------- ----- ------- ----------------
  **HPV vaccination status**                                                                                           
  Vaccinated (min 1 dose)                                              310               72.6%           70    31.4%   **\<0.001 \***
  Not vaccinated                                                       117               27.4%           153   68.6%   
  **Who should pay for this vaccination**                                                                              
  Private Insurance                                                    269               63.0%           126   56.5%   0.08
  State health system                                                  100               23.4%           61    27.4%   
  From my pocket                                                       23                5.4%            10    4.5%    
  Others                                                               10                2.3%            6     2.7%    
  Don't know                                                           25                5.9%            20    9.0%    
  **Who should get vaccinated**                                                                                        
  Women only                                                           301               70.5%           185   83.0%   **0.0003**
  Men and women                                                        121               28.3%           37    16.6%   
  Men only                                                             5                 1.2%            1     0.4%    
  **When vaccine should be given**                                                                                     
  Before the first sex encounter                                       126               29.5%           94    42.2%   **0.0009**
  Casual relationship                                                  139               32.6%           67    30.0%   
  If more than one partner                                             112               26.2%           43    19.3%   
  Any time                                                             50                11.7%           19    8.5%    
  **Would you recommend the HPV vaccine?**                                                                             
  Yes                                                                  382               89.5%           201   90.1%   0.69
  No                                                                   45                10.5%           22    9.9%    
  **Do you think that the vaccine should be offered free of charge**                                                   
  Yes                                                                  415               97.2%           220   98.7%   0.45
  No                                                                   12                2.8%            3     1.3%    

\* Bold font indicates a statistical significance.

vaccines-07-00130-t004_Table 4

###### 

Logistic regression predicting HPV vaccination (min one dose).

                                    aOR (95 CI)
  --------------------------------- ------------------------
  **Gender**                        
  Men                               Referent
  Women                             **5.79 (4.0 6--8.25)**
  **Birthplace**                    
  Switzerland                       Referent
  Europe                            **1.65 (1.42--1.92)**
  Other                             0.81 (0.66--1.03)
  **Relationship status**           
  Married                           Referent
  Not married                       **0.68 (0.22--0.72)**
  **Smoker**                        
  Yes                               Referent
  No                                **1.51 (1.05--2.81)**
  **Ever had sexual Intercourse**   
  Yes                               Referent
  No                                **0.50 (0.30--0.83)**
  **Currently sexually active**     
  Yes                               Referent
  No                                **0.31 (0.10--0.95)**

Only odds ratio significant in the univariate model is presented in this table aOR adjusted OR for significant univariate predictors. Bold font indicates a statistical significance and a 95% confidence interval.
